Clinical trial · Observational
Is Lipid Mapping an Effective Early Detection Tool for Breast Cancer in High-risk Populations?
Is Lipid Composition Mapping Using Magnetic Resonance Imaging an Effective Early Detection Tool for Breast Cancer in High Risk Populations?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate if lipid composition mapping using magnetic resonance imaging could improve early and accurate cancer detection in genetic mutation carriers at high risk of breast cancer. It is hypothesised that there is a significant difference in the extent of spatial variation in lipid composition in breast from MRI between genetic mutation carriers and patients with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic resonance imaging (MRI) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- High-risk
- description
- Female participants confirmed to be BRCA1/2 or TP53 gene carriers
- interventionNames
- Procedure: Magnetic resonance imaging (MRI)
- label
- Patients
- description
- Female participants confirmed to have invasive ductal carcinoma of the breast
- interventionNames
- Procedure: Magnetic resonance imaging (MRI)
Primary outcomes (3)
- measure
- Saturated fatty acids in breasts of patients and high-risk group
- timeFrame
- Baseline
- description
- Saturated fatty acids (SFA) from tumour border and fatty tissue in patients and fibroglandular and fatty tissue in high-risk group SFA will be measured in percentage (%)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * female over 18 years old * BRCA1/2 or TP53 gene carriers (high-risk group) * invasive ductal carcinoma of the breast (patient group) * not having any metabolic disorders (e.g., diabetes) * not on any long term medications that may affect lipid metabolism (e.g., statins) Exclusion Criteria: * female under 18 years old * male * affected by metabolic disorders (e.g., diabetes) * on long term medications that affect lipid metabolism (e.g., statins) * contraindicated for MR investigations (poor renal function and metal implants) * concurrent cancer in other sites * concurrent hormone treatment, chemotherapy or underwent surgery * non-English speakers
References
Publications (0)
Data not yet available